Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 124   

Articles published

JNJ 124.39 -0.64 (-0.51%)
price chart
3 Important Takeaways From Johnson & Johnson's Second-Quarter Earnings
Johnson & Johnson (NYSE:JNJ) is a healthcare Goliath that operates consumer healthcare, pharmaceuticals, and medical device businesses.
Why I'm Easing Off Johnson & Johnson  Seeking Alpha
Johnson & Johnson Subsidiary Acclarent Settles Medical Device-Related ...
Acclarent, a subsidiary of Johnson & Johnson, pays $18 million in a U.S. settlement to resolve medical device-related accusations.
Johnson & Johnson subsidiary pays $18 million to U.S. in settlement  UPI.com
Johnson & Johnson's talcum controversy  Pulse Headlines
Can Big Still Be Beautiful?
For the 56-year-old CEO of Johnson & Johnson, this drizzly morning in May—Analyst Day—offered a chance to put some show behind a tell he had been making for the previous four years, or since he had assumed the reins of the $70-billion-a-year health ...
Two Former Johnson & Johnson Execs Just Got Convicted for Improper Marketing
A federal jury on Wednesday convicted two former top executives at medical device company Acclarent, a unit of drug giant Johnson & Johnson JNJ -0.10% , for improperly marketing a sinus-opening device. The Boston jury found Facteau and Fabian guilty ...
Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson
In early May, I pitted medical conglomerate Johnson & Johnson (NYSE:JNJ) against robotic-surgery specialist Intuitive Surgical (NASDAQ:ISRG) to see which company was a better buy at the time.
Johnson & Johnson Raises Guidance, Buoyed by Pharma Growth
Johnson & Johnson JNJ -0.10 % on Tuesday raised its guidance for the year again as the health-care giant topped expectations in the latest quarter, helped by growth in its pharmaceutical business.
What to expect from Johnson & Johnson earnings  MarketWatch
Johnson & Johnson tops 2Q forecasts despite profit drop  U.S. News & World Report
Johnson & Johnson: A Dividend King With 54 Years Of Dividend Increases (Part ...
Johnson & Johnson is extremely diversified in the medical health field with new drugs leading the way. The company is a defensive business that will make money in a recession.
Johnson & Johnson (JNJ) Shares are Up 1.65%  Trade Calls
Johnson & Johnson (JNJ) Stake Increased by Prudential Financial Inc.  Community Financial News
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter
Johnson & Johnson (JNJ) reported its second quarter 2016 earnings results on Tuesday, July 19. The company beat both revenue and earnings estimates for the quarter, helping to fuel continued momentum in U.S.
Analysts Advise About Johnson & Johnson (NYSE:JNJ)  Zergwatch
Noteworthy Analyst's Rating to Observe: Johnson & Johnson (NYSE:JNJ ...  Street Updates
Can Johnson & Johnson Keep Soaring Higher?
Johnson & Johnson has been tracing out an almost completely uninterrupted rally since the mid-January low. This impressive performance includes six straight higher monthly highs as shares moved past the 2014 and 2015 peaks.
Johnson & Johnson's Unstylish Sprawl Looks Good
Johnson & Johnson has bucked that trend, even as some of its units have struggled. But sometimes being out of step is the right move.